{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:39:33Z","timestamp":1794321573639,"version":"4.9.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The PD-1\/PD-L1 pathway in mucosal immunity is currently actively explored and considered as a target for inflammatory bowel disease (IBD) treatment. However, systemic PD-L1 administration may cause unpredictable adverse effects due to immunosuppression. Here we show that reactive oxygen species (ROS)-responsive nanoparticles enhance the efficacy and safety of PD-L1 in a mouse colitis model. The nanoparticles control the accumulation and release of PD-L1 fused to Fc (PD-L1-Fc) at inflammatory sites in the colon. The nanotherapeutics shows superiority in alleviating inflammatory symptoms over systemic PD-L1-Fc administration and mitigates the adverse effects of PD-L1-Fc administration. The nanoparticles-formulated PD-L1-Fc affects production of proinflammatory and anti-inflammatory cytokines, attenuates the infiltration of macrophages, neutrophils, and dendritic cells, increases the frequencies of Treg, Th1 and Tfh cells, reshapes the gut microbiota composition; and increases short-chain fatty acid production. In summary, PD-L1-Fc-decorated nanoparticles may provide an effective and safe strategy for the targeted treatment of IBD.<\/jats:p>","DOI":"10.1038\/s41467-024-46025-0","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T16:02:31Z","timestamp":1708704151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Targeted delivery of Fc-fused PD-L1 for effective management of acute and chronic colitis"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5565-527X","authenticated-orcid":false,"given":"Xudong","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0764-0572","authenticated-orcid":false,"given":"Yangyang","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4400-919X","authenticated-orcid":false,"given":"Dinglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1400-0728","authenticated-orcid":false,"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"46025_CR1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41575-022-00593-y","volume":"19","author":"M Agrawal","year":"2022","unstructured":"Agrawal, M., Allin, K. H., Petralia, F., Colombel, J. F. & Jess, T. Multiomics to elucidate inflammatory bowel disease risk factors and pathways. Nat. Rev. Gastroenterol. Hepatol. 19, 399\u2013409 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"46025_CR2","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1053\/j.gastro.2021.02.019","volume":"160","author":"T Kuwada","year":"2021","unstructured":"Kuwada, T. et al. Identification of an anti-Integrin \u03b1v\u03b26 autoantibody in patients with ulcerative colitis. Gastroenterology 160, 2383\u20132394.e21 (2021).","journal-title":"Gastroenterology"},{"key":"46025_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102846","volume":"20","author":"HT Meitei","year":"2021","unstructured":"Meitei, H. T., Jadhav, N. & Lal, G. CCR6-CCL20 axis as a therapeutic target for autoimmune diseases. Autoimmun. Rev. 20, 102846 (2021).","journal-title":"Autoimmun. Rev."},{"key":"46025_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.chom.2021.11.001","volume":"30","author":"M Alexander","year":"2022","unstructured":"Alexander, M. et al. Human gut bacterial metabolism drives Th17 activation and colitis. Cell Host Microbe 30, 17\u201330.e9 (2022).","journal-title":"Cell Host Microbe"},{"key":"46025_CR5","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.cgh.2020.02.009","volume":"18","author":"L Beaugerie","year":"2020","unstructured":"Beaugerie, L., Rahier, J. F. & Kirchgesner, J. Predicting, preventing, and managing treatment-related complications in patients with inflammatory bowel diseases. Clin. Gastroenterol. Hepatol. 18, 1324\u20131335.e2 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"46025_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106146","volume":"178","author":"H Luo","year":"2022","unstructured":"Luo, H. et al. Emerging pharmacotherapy for inflammatory bowel diseases. Pharmacol. Res. 178, 106146 (2022).","journal-title":"Pharmacol. Res."},{"key":"46025_CR7","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1093\/ecco-jcc\/jjac035","volume":"16","author":"C Cottron","year":"2022","unstructured":"Cottron, C. et al. How to manage inflammatory bowel disease patients when they withdraw anti-tumour necrosis factor [Anti-TNF] due to severe anti-TNF-induced skin lesions? A multicentre cohort study. J. Crohns Colitis 16, 1202\u20131210 (2022).","journal-title":"J. Crohns Colitis"},{"key":"46025_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41590-021-01125-7","volume":"23","author":"D Sugiura","year":"2022","unstructured":"Sugiura, D. et al. PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity. Nat. Immunol. 23, 399\u2013410 (2022).","journal-title":"Nat. Immunol."},{"key":"46025_CR9","doi-asserted-by":"publisher","first-page":"e20182232","DOI":"10.1084\/jem.20182232","volume":"218","author":"CL Tan","year":"2021","unstructured":"Tan, C. L. et al. PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. J. Exp. Med. 218, e20182232 (2021).","journal-title":"J. Exp. Med."},{"key":"46025_CR10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2120149119","volume":"119","author":"AN Policheni","year":"2022","unstructured":"Policheni, A. N. et al. PD-1 cooperates with AIRE-mediated tolerance to prevent lethal autoimmune disease. Proc. Natl. Acad. Sci. USA 119, e2120149119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"46025_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI159925","volume":"132","author":"J Becker-Gotot","year":"2022","unstructured":"Becker-Gotot, J. et al. Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs. J. Clin. Investig. 132, e159925 (2022).","journal-title":"J. Clin. Investig."},{"key":"46025_CR12","doi-asserted-by":"publisher","first-page":"9165","DOI":"10.3390\/ijms21239165","volume":"21","author":"M Chulkina","year":"2020","unstructured":"Chulkina, M., Beswick, E. J. & Pinchuk, I. V. Role of PD-L1 in gut mucosa tolerance and chronic inflammation. Int. J. Mol. Sci. 21, 9165 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"46025_CR13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.14309\/ajg.0000000000000497","volume":"115","author":"E Bellaguarda","year":"2020","unstructured":"Bellaguarda, E. & Hanauer, S. Checkpoint Inhibitor-Induced Colitis. Am. J. Gastroenterol. 115, 202\u2013210 (2020).","journal-title":"Am. J. Gastroenterol."},{"key":"46025_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102440","volume":"109","author":"DL Nielsen","year":"2022","unstructured":"Nielsen, D. L., Juhl, C. B., Chen, I. M., Kellermann, L. & Nielsen, O. H. Immune checkpoint Inhibitor-induced diarrhea and colitis: incidence and management. a systematic review and Meta-analysis. Cancer Treat Rev. 109, 102440 (2022).","journal-title":"Cancer Treat Rev."},{"key":"46025_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.celrep.2014.01.020","volume":"6","author":"L Scandiuzzi","year":"2014","unstructured":"Scandiuzzi, L. et al. Tissue-expressed B7-H1 critically controls intestinal inflammation. Cell Rep. 6, 625\u2013632 (2014).","journal-title":"Cell Rep."},{"key":"46025_CR16","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1093\/ecco-jcc\/jjx081","volume":"11","author":"C Coutzac","year":"2017","unstructured":"Coutzac, C. et al. Colon immune-related adverse events: Anti-CTLA-4 and Anti-PD-1 blockade induce distinct immunopathological entities. J. Crohns Colitis 11, 1238\u20131246 (2017).","journal-title":"J. Crohns Colitis"},{"key":"46025_CR17","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","volume":"182","author":"AM Luoma","year":"2020","unstructured":"Luoma, A. M. et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell. 182, 655\u2013671.e22 (2020).","journal-title":"Cell."},{"key":"46025_CR18","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/gutjnl-2014-307311","volume":"64","author":"MY Song","year":"2015","unstructured":"Song, M. Y. et al. Protective effects of Fc-fused PD-L1 on two different animal models of colitis. Gut 64, 260\u2013271 (2015).","journal-title":"Gut"},{"key":"46025_CR19","doi-asserted-by":"publisher","first-page":"e2106265","DOI":"10.1002\/adma.202106265","volume":"34","author":"F Xu","year":"2022","unstructured":"Xu, F. et al. Mesenchymal stem cell-derived extracellular vesicles with High PD-L1 expression for autoimmune diseases treatment. Adv. Mater 34, e2106265 (2022).","journal-title":"Adv. Mater"},{"key":"46025_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/adhm.201400299","volume":"4","author":"D Zhang","year":"2015","unstructured":"Zhang, D. et al. Biocompatible reactive oxygen species (ROS)-responsive nanoparticles as superior drug delivery vehicles. Adv. Healthcare Mater 4, 69\u201376 (2015).","journal-title":"Adv. Healthcare Mater"},{"key":"46025_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119730","volume":"232","author":"R Ni","year":"2020","unstructured":"Ni, R. et al. Reactive oxygen species-responsive dexamethasone-loaded nanoparticles for targeted treatment of rheumatoid arthritis via suppressing the iRhom2\/TNF-\u03b1\/BAFF signaling pathway. Biomaterials 232, 119730 (2020).","journal-title":"Biomaterials"},{"key":"46025_CR22","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/s41385-019-0205-x","volume":"12","author":"G Aviello","year":"2019","unstructured":"Aviello, G. et al. Colitis susceptibility in mice with reactive oxygen species deficiency is mediated by mucus barrier and immune defense defects. Mucosal Immunol 12, 1316\u20131326 (2019).","journal-title":"Mucosal Immunol"},{"key":"46025_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-019-0537-4","volume":"17","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Targeted delivery of antibiotics to the infected pulmonary tissues using ROS-responsive nanoparticles. J. Nanobiotechnol. 17, 103 (2019).","journal-title":"J. Nanobiotechnol."},{"key":"46025_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201900610","volume":"6","author":"C Li","year":"2019","unstructured":"Li, C. et al. A proresolving peptide nanotherapy for site-specific treatment of inflammatory bowel disease by regulating proinflammatory microenvironment and gut microbiota. Adv. Sci. 6, 1900610 (2019).","journal-title":"Adv. Sci."},{"key":"46025_CR25","doi-asserted-by":"publisher","first-page":"6286","DOI":"10.1073\/pnas.1818164116","volume":"116","author":"Y Cao","year":"2019","unstructured":"Cao, Y. et al. Transcriptional factor ATF3 protects against colitis by regulating follicular helper T cells in Peyer\u2019s patches. Proc. Natl. Acad. Sci. USA 116, 6286\u20136291 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"46025_CR26","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1136\/gutjnl-2019-319850","volume":"69","author":"JN Clough","year":"2020","unstructured":"Clough, J. N., Omer, O. S., Tasker, S., Lord, G. M. & Irving, P. M. Regulatory T-cell therapy in Crohn\u2019s disease: challenges and advances. Gut 69, 942\u2013952 (2020).","journal-title":"Gut"},{"key":"46025_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202002406","volume":"32","author":"P Feng","year":"2020","unstructured":"Feng, P., Cao, Z., Wang, X., Li, J. & Liu, J. On-demand bacterial reactivation by restraining within a triggerable nanocoating. Adv. Mater. 32, e2002406 (2020).","journal-title":"Adv. Mater."},{"key":"46025_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41385-020-0296-4","volume":"14","author":"A Iljazovic","year":"2021","unstructured":"Iljazovic, A. et al. Perturbation of the gut microbiome by Prevotella spp. enhances host susceptibility to mucosal inflammation. Mucosal Immunol. 14, 113\u2013124 (2021).","journal-title":"Mucosal Immunol."},{"key":"46025_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.691480","volume":"12","author":"S Bruscoli","year":"2021","unstructured":"Bruscoli, S., Febo, M., Riccardi, C. & Migliorati, G. Glucocorticoid therapy in inflammatory bowel disease: mechanisms and clinical practice. Front. Immunol. 12, 691480 (2021).","journal-title":"Front. Immunol."},{"key":"46025_CR30","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.3748\/wjg.v25.i21.2539","volume":"25","author":"MD Voskuil","year":"2019","unstructured":"Voskuil, M. D., Bangma, A., Weersma, R. K. & Festen, E. A. M. Predicting (side) effects for patients with inflammatory bowel disease: the promise of pharmacogenetics. World J. Gastroenterol. 25, 2539\u20132548 (2019).","journal-title":"World J. Gastroenterol."},{"key":"46025_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.clim.2018.03.004","volume":"206","author":"KH Katsanos","year":"2019","unstructured":"Katsanos, K. H., Papamichael, K., Feuerstein, J. D., Christodoulou, D. K. & Cheifetz, A. S. Biological therapies in inflammatory bowel disease: beyond anti-TNF therapies. Clin. Immunol. 206, 9\u201314 (2019).","journal-title":"Clin. Immunol."},{"key":"46025_CR32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S2468-1253(21)00223-5","volume":"7","author":"K Papamichael","year":"2022","unstructured":"Papamichael, K. et al. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol. Hepatol. 7, 171\u2013185 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"46025_CR33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ijid.2017.01.028","volume":"56","author":"M Rao","year":"2017","unstructured":"Rao, M., Valentini, D., Dodoo, E., Zumla, A. & Maeurer, M. Anti-PD-1\/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. Int. J. Infect. Dis. 56, 221\u2013228 (2017).","journal-title":"Int. J. Infect. Dis."},{"key":"46025_CR34","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41551-018-0241-y","volume":"2","author":"JP Cooke","year":"2018","unstructured":"Cooke, J. P. & Ferrari, M. Inflammation-targeted vascular nanomedicine. Nat. Biomed. Eng. 2, 269\u2013270 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"46025_CR35","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/ibd\/izz205","volume":"25","author":"F Giron","year":"2019","unstructured":"Giron, F., Past\u00f3, A., Tasciotti, E. & Abraham, B. P. Nanotechnology in the treatment of inflammatory bowel disease. Inflamm. Bowel Dis. 25, 1871\u20131880 (2019).","journal-title":"Inflamm. Bowel Dis."},{"key":"46025_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12929-020-00702-6","volume":"28","author":"A Pant","year":"2021","unstructured":"Pant, A., Mackraj, I. & Govender, T. Advances in sepsis diagnosis and management: a paradigm shift towards nanotechnology. J. Biomed. Sci. 28, 6 (2021).","journal-title":"J. Biomed. Sci."},{"key":"46025_CR37","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/s41565-021-00928-x","volume":"16","author":"N Dammes","year":"2021","unstructured":"Dammes, N. et al. Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics. Nat. Nanotechnol. 16, 1030\u20131038 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"46025_CR38","doi-asserted-by":"publisher","first-page":"13037","DOI":"10.1021\/acsnano.2c05558","volume":"16","author":"J Xu","year":"2022","unstructured":"Xu, J. et al. Design of diselenide-bridged hyaluronic acid nano-antioxidant for efficient ROS scavenging to relieve colitis. ACS Nano 16, 13037\u201313048 (2022).","journal-title":"ACS Nano"},{"key":"46025_CR39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.biomaterials.2017.07.035","volume":"143","author":"Y Dou","year":"2017","unstructured":"Dou, Y. et al. Non-proinflammatory and responsive nanoplatforms for targeted treatment of atherosclerosis. Biomaterials 143, 93\u2013108 (2017).","journal-title":"Biomaterials"},{"key":"46025_CR40","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1136\/gutjnl-2020-321094","volume":"70","author":"L Ai","year":"2021","unstructured":"Ai, L. et al. Synbindin restrains proinflammatory macrophage activation against microbiota and mucosal inflammation during colitis. Gut 70, 2261\u20132272 (2021).","journal-title":"Gut"},{"key":"46025_CR41","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1136\/gutjnl-2021-324725","volume":"71","author":"M Leppkes","year":"2022","unstructured":"Leppkes, M. et al. Neutrophils prevent rectal bleeding in ulcerative colitis by peptidyl-arginine deiminase-4-dependent immunothrombosis. Gut 71, 2414\u20132429 (2022).","journal-title":"Gut"},{"key":"46025_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105779","volume":"171","author":"A Dos Santos Ramos","year":"2021","unstructured":"Dos Santos Ramos, A., Viana, G. C. S., de Macedo Brigido, M. & Almeida, J. F. Neutrophil extracellular traps in inflammatory bowel diseases: implications in pathogenesis and therapeutic targets. Pharmacol. Res. 171, 105779 (2021).","journal-title":"Pharmacol. Res."},{"key":"46025_CR43","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/eji.201040379","volume":"40","author":"Y Mikami","year":"2010","unstructured":"Mikami, Y. et al. Competition between colitogenic Th1 and Th17 cells contributes to the amelioration of colitis. Eur. J. Immunol. 40, 2409\u20132422 (2010).","journal-title":"Eur. J. Immunol."},{"key":"46025_CR44","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00281-019-00732-9","volume":"41","author":"Y Hagihara","year":"2019","unstructured":"Hagihara, Y. et al. Epigenetic regulation of T helper cells and intestinal pathogenicity. Semin. Immunopathol. 41, 379\u2013399 (2019).","journal-title":"Semin. Immunopathol."},{"key":"46025_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101480","volume":"52","author":"KE Pauken","year":"2021","unstructured":"Pauken, K. E., Torchia, J. A., Chaudhri, A., Sharpe, A. H. & Freeman, G. J. Emerging concepts in PD-1 checkpoint biology. Semin. Immunol. 52, 101480 (2021).","journal-title":"Semin. Immunol."},{"key":"46025_CR46","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/cmi.2017.70","volume":"15","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. The altered PD-1\/PD-L1 pathway delivers the \u2018one-two punch\u2019 effects to promote the Treg\/Th17 imbalance in pre-eclampsia. Cell Mol. Immunol. 15, 710\u2013723 (2018).","journal-title":"Cell Mol. Immunol."},{"key":"46025_CR47","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/hep.31921","volume":"74","author":"C Yi","year":"2021","unstructured":"Yi, C. et al. Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC. Hepatology 74, 2544\u20132560 (2021).","journal-title":"Hepatology"},{"key":"46025_CR48","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/annrheumdis-2021-221985","volume":"81","author":"Z Zhao","year":"2022","unstructured":"Zhao, Z. et al. Tfh cells with NLRP3 inflammasome activation are essential for high-affinity antibody generation, germinal centre formation and autoimmunity. Ann. Rheum. Dis. 81, 1006\u20131012 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"46025_CR49","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jaut.2018.09.001","volume":"96","author":"R Zhang","year":"2019","unstructured":"Zhang, R. et al. T follicular helper cells restricted by IRF8 contribute to T cell-mediated inflammation. J. Autoimmun.96, 113\u2013122 (2019).","journal-title":"J. Autoimmun"},{"key":"46025_CR50","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41575-020-0331-7","volume":"17","author":"MR Kudelka","year":"2020","unstructured":"Kudelka, M. R., Stowell, S. R., Cummings, R. D. & Neish, A. S. Intestinal epithelial glycosylation in homeostasis and gut microbiota interactions in IBD. Nat. Rev. Gastroenterol. Hepatol. 17, 597\u2013617 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"46025_CR51","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/ecco-jcc\/jjab159","volume":"16","author":"R Suau","year":"2022","unstructured":"Suau, R., Pardina, E., Dom\u00e8nech, E., Lor\u00e9n, V. & Many\u00e9, J. The complex relationship between microbiota, immune response and creeping fat in Crohn\u2019s disease. J. Crohns Colitis 16, 472\u2013489 (2022).","journal-title":"J. Crohns Colitis"},{"key":"46025_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103293","volume":"66","author":"S Deleu","year":"2021","unstructured":"Deleu, S., Machiels, K., Raes, J., Verbeke, K. & Vermeire, S. Short chain fatty acids and its producing organisms: an overlooked therapy for IBD? EBioMedicine 66, 103293 (2021).","journal-title":"EBioMedicine"},{"key":"46025_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109332","volume":"36","author":"L Dupraz","year":"2021","unstructured":"Dupraz, L. et al. Gut microbiota-derived short-chain fatty acids regulate IL-17 production by mouse and human intestinal \u03b3\u03b4 T cells. Cell Rep. 36, 109332 (2021).","journal-title":"Cell Rep."},{"key":"46025_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodres.2022.111390","volume":"157","author":"CJ Hong","year":"2022","unstructured":"Hong, C. J., Chen, S. Y., Hsu, Y. H. & Yen, G. C. Protective effect of fermented okara on the regulation of inflammation, the gut microbiota, and SCFAs production in rats with TNBS-induced colitis. Food Res. Int. 157, 111390 (2022).","journal-title":"Food Res. Int."},{"key":"46025_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05901-2","volume":"9","author":"M Sun","year":"2018","unstructured":"Sun, M. et al. Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis. Nat. Commun. 9, 3555 (2018).","journal-title":"Nat. Commun."},{"key":"46025_CR56","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/nprot.2017.044","volume":"12","author":"S Wirtz","year":"2017","unstructured":"Wirtz, S. et al. Chemically induced mouse models of acute and chronic intestinal inflammation. Nat. Protoc. 12, 1295\u20131309 (2017).","journal-title":"Nat. Protoc."},{"key":"46025_CR57","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1038\/nprot.2006.446","volume":"1","author":"C Becker","year":"2006","unstructured":"Becker, C., Fantini, M. C. & Neurath, M. F. High resolution colonoscopy in live mice. Nat. Protoc. 1, 2900\u20132904 (2006).","journal-title":"Nat. Protoc."},{"key":"46025_CR58","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1136\/gutjnl-2012-303207","volume":"63","author":"ME Johansson","year":"2014","unstructured":"Johansson, M. E. et al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut 63, 281\u2013291 (2014).","journal-title":"Gut"},{"key":"46025_CR59","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13287-019-1169-1","volume":"10","author":"X Zhang","year":"2019","unstructured":"Zhang, X. et al. Overexpressing p130\/E2F4 in mesenchymal stem cells facilitates the repair of injured alveolar epithelial cells in LPS-induced ARDS mice. Stem Cell Res. Ther. 10, 74 (2019).","journal-title":"Stem Cell Res. Ther."},{"key":"46025_CR60","doi-asserted-by":"publisher","first-page":"D18","DOI":"10.1093\/nar\/gkac1073","volume":"51","author":"CNCB-NGDC Members and Partners.","year":"2023","unstructured":"CNCB-NGDC Members and Partners. Database resources of the national genomics data center, China national center for bioinformation in 2023. Nucleic Acids Res. 51, D18\u2013D28 (2023).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46025-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46025-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46025-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T07:03:08Z","timestamp":1708758188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46025-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["46025"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-46025-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"20 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1673"}}